相关实验视频
Updated: May 21, 2025

12:38
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
2.4K
甲基受体2:一种潜在的治疗点,用于与炎症相关的疾病
Jiaying Wang1, Zhishuo Miao2, Yinhuang Gao2
1School of Pharmacy, Hunan Provincial Maternal and Child Health Care Hospital, University of South China, Hengyang, 421001, China.
Pharmacological reports : PR
|March 19, 2025
概括
甲基受体2 (FPR2) 在炎症中充当双刃剑,调解有害和有益的反应. 了解FPR2 的理解
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 甲基受体2 (FPR2) 是一种参与炎症的G蛋白结合受体.
- FPR2表现出双重作用,调解着促进炎症和抗炎症的作用.
- 它的功能很复杂,在各种炎症状况中并不完全理解.
研究的目的:
- 审查FPR2在各种炎症相关疾病中的作用.
- 探索FPR2作为潜在的炎症性疾病治疗点.
- 总结一下FPR2激动剂药物发现的最新进展.
主要方法:
- 关于FPR2参与炎症的文献评论.
- 分析FPR2的调节网络和信号通路.
- 对外源性FPR2激动剂和跨物种受体表达的检查.
主要成果:
- FPR2分布广泛,并与影响多个器官的炎症性疾病有关.
- FPR2的双重活动为治疗干预带来了挑战和机会.
- 报告指出,FPR2激动剂的开发和理解跨物种表达的进展.
结论:
- 在炎症性疾病中,FPR2扮演着重要的,多方面的角色.
- 准FPR2为新型抗炎疗法提供了潜力.
- 需要进一步的研究来阐明针对药物开发的精确监管机制.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
Inflammatory Response
1.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.7K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
140
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
140

